Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Phoenix Molecular Designs
Study ID
NCT04115306
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PMD-026 — DRUG
    Investigational Drug
  • fulvestrant — DRUG
    SERDs

Study Details

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

Key Dates

Start date
Nov 14, 2019
Status verified
Jan 2026
Primary completion
Sep 30, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
61 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Oral PMD-026 in combination with fulvestrant
    Daily dosing of PMD-026 with fulvestrant dosing according to package insert

Primary Outcome Measure

Safety and tolerability of PMD-026 in combination with fulvestrant in patients with HR+/HER2- previously treated breast cancer [ Time Frame: 6 weeks ]

Central Contacts

Locations (11)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer CenterGilbertArizona85234
Nibu Mathew
[email protected]
480-256-5412
Stephanie Hernandez, CRC
[email protected]
Hung T Khong, MD (PRINCIPAL_INVESTIGATOR)
City of HopeDuarteCalifornia91010
Felicia Lewis
[email protected]
626-218-1133
Hope Rugo, MD (PRINCIPAL_INVESTIGATOR)
City of Hope Orange County, LennarIrvineCalifornia92618
Ankita Singh
[email protected]
626-218-1133
Hope Rugo, MD (PRINCIPAL_INVESTIGATOR)
University of California, Los Angeles (UCLA)Los AngelesCalifornia90095
Monica Rocha
[email protected]
310-998-4747
Nicolaos Palaskas, MD (PRINCIPAL_INVESTIGATOR)
Moffitt Cancer CenterTampaFlorida33612
Neveen Abdo
[email protected]
8137454412
Hyo Han, MD (PRINCIPAL_INVESTIGATOR)
City of Hope ChicagoZionIllinois60099
Heather Johansen
[email protected]
8334393302
Ajaz Khan, MD (PRINCIPAL_INVESTIGATOR)
Massachusetts General Hospital Cancer CenterBostonMassachusetts02114
Natalie Moffett
[email protected]
617-724-1864
Seth Wander, MD (PRINCIPAL_INVESTIGATOR)
Profound ResearchFarmington HillsMichigan48334
Heather Austin
[email protected]
585.216.7617
[email protected]
248-419-3456
Jeffrey Margolis, MD (PRINCIPAL_INVESTIGATOR)
Ohio State UniversityColumbusOhio43210
Emily Viall, RN
[email protected]
614-814-1114
Robert Wesolowski, MD
[email protected]
Robert Wesolowski, MD (PRINCIPAL_INVESTIGATOR)
Oncology ConsultantsHoustonTexas77030-
South Texas Accelerated Research TherapeuticsSan AntonioTexas78229
Isabel Jimenez, RN, MSN
[email protected]
210-593-5265
Muralidhar Beeram, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Gilbert, AZ

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Banner MD Anderson Cancer Center· Gilbert, AZCity of Hope· Duarte, CACity of Hope Orange County, Lennar· Irvine, CAUniversity of California, Los Angeles (UCLA)· Los Angeles, CAMoffitt Cancer Center· Tampa, FLCity of Hope Chicago· Zion, IL

Related Studies